Detalhe da pesquisa
1.
CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema.
N Engl J Med
; 390(5): 432-441, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38294975
2.
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
N Engl J Med
; 385(6): 493-502, 2021 08 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215024
3.
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.
N Engl J Med
; 378(5): 439-448, 2018 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29385370
4.
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. Reply.
N Engl J Med
; 385(18): 1722-1723, 2021 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-34706181
5.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med
; 366(6): 520-9, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149876
6.
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet
; 381(9869): 817-24, 2013 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-23312829
7.
Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 381(9861): 125-32, 2013 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23158522
8.
Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med
; 364(6): 514-23, 2011 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21306238
9.
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Lancet
; 378(9808): 2005-2012, 2011 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22119496
10.
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial.
Lancet
; 372(9637): 449-56, 2008 Aug 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18653228
11.
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.
Curr Hematol Malig Rep
; 14(1): 47-55, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30666506
12.
Estimands and the Patient Journey: Addressing the Right Question in Oncology Clinical Trials.
JCO Precis Oncol
; 3: 1-10, 2019 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35100723
13.
Future directions in the treatment of hormone-sensitive advanced breast cancer: the RAD001 (Everolimus)-letrozole clinical program.
Semin Oncol
; 33(2 Suppl 7): S18-25, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16730273
14.
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
Cancer Chemother Pharmacol
; 57(6): 761-71, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16172907
15.
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
J Clin Oncol
; 34(5): 419-26, 2016 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503204
16.
Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.
J Clin Oncol
; 21(9): 1866-73, 2003 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12721265
17.
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
J Clin Oncol
; 22(2): 269-76, 2004 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14722035
18.
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Eur J Cancer
; 41(9): 1291-9, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15939265
19.
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors.
Clin Cancer Res
; 10(4): 1289-98, 2004 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14977827
20.
Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
Ann N Y Acad Sci
; 1291: 14-32, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23659703